NEW DELHI : Zydus Cadila on Friday announced that it has signed a non-exclusive licensing agreement with Gilead Sciences Inc for the manufacturing and sale of the promising covid-19 drug remdesivir.This makes Zydus Cadila the fifth company in India and sixth in the world to sign licensing agreement for Gilead’s novel intravenous drug, which has received emergency use authorisation (EUA) in both the US, India and a few other countries for the treatment of covid-19.Last month, Gilead Sciences Inc signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers – Cipla Ltd, Jubilant Life Sciences, Hetero Labs Ltd, Mylan and Ferozsons Laboratories – on a royalty-free basis.Of the five, Ferozsons Laboratories is.